

### REMARKS

Claims 51-77 are active. Pages 7, 8, 30 and 40 of the specification have been amended to refer to the appropriate sequence identifiers. The specification has been amended (as it was in the parent application) to correct two apparent typographical errors on pages 30 and 40.

Please replace the original drawings (on 22 sheets) with the formal drawings attached to this response (27 sheets). The formal drawings correspond to those submitted in the parent application and include the drawing revisions required in the parent application.

Claims 51-58 find support in original Claim 13 and in the specification on pages 28-30, which describe adenylate cyclase assays. Claims 59-64 find support in original Claim 28 and on pages 31-34 which describe assays involving collagen. Claims 65-74 find support in original Claim 30 and pages 35-38 of the specification. Page 36, lines 4, 15 and 21, respectively, describe the enzyme, ion transport or signal transduction assays of Claims 72-74. Product Claims 75-77 find support as indicated above for the corresponding method claims and in original Claims 14 and on page 40, lines 7-16, of the specification. Accordingly, the Applicants do not believe that any new matter has been added. Favorable consideration is respectfully requested.

CONCLUSION

The Applicants submit that this application is now ready for an early examination on the merits.



22850

Tel.: (703) 413-3000  
Fax: (703) 413-2220

I:\ATTY\TMC\06600158US-PR.DOC

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER, & NEUSTADT, P.C.

A handwritten signature in black ink, appearing to read "Norman F. Oblon", written over a horizontal line.

Norman F. Oblon  
Attorney of Record  
Registration No.: 24,618

Thomas M. Cunningham  
Registration No. 45,394